ENTITY

OSE Immuno (OSE FP)

35
Analysis
Health CareFrance
OSE Immunotherapeutics SA is a biotechnology company based in France, developing immunotherapy products against invasive/metastatic late-stage cancers.
more
Refresh
bullishOSE Immuno
27 Jun 2024 19:12Issuer-paid

OSE Immunotherapeutics - Another partnership with expansion into CAR-T

OSE Immunotherapeutics has entered into a commercial and revenue sharing agreement with the Memorial Sloan Kettering Cancer Center (MSK), focused...

Share
bullishOSE Immuno
06 Jun 2024 19:10Issuer-paid

OSE Immunotherapeutics - Strong momentum in deal flow

OSE Immunotherapeutic’s FY24 has started off with a series of major wins, significantly bolstering the company’s clinical pipeline and liquidity....

Share
bullishOSE Immuno
24 May 2024 01:10Issuer-paid

OSE Immunotherapeutics - Another partnership win – Boehringer Ingelheim

OSE Immunotherapeutics has announced a considerable expansion of its partnership with Boehringer Ingelheim (BI), including the start of two new...

Share
bullishOSE Immuno
19 Apr 2024 13:10Issuer-paid

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is...

Share
bullishOSE Immuno
12 Apr 2024 19:10Issuer-paid

OSE Immunotherapeutics - Funding accelerates Tedopi clinical development

Despite the challenging macroeconomic environment, OSE announced an encouraging funding win with the receipt of €8.4m in non-dilutive public...

Share
x